Clinical trialPhase 1Completed
Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma
Dose Escalation Study of the Combination of ZD6474, Gemcitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- July 2006
- Expected end
- June 2009
- Enrollment
- 8 participants
- Sites
- 2
- Primary outcomes
- Define Maximum Tolerated Dose (MTD); Define Recommended Dose (RD)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 29 August 2016
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to define th Maximum Tolerated Dose (MTD) and the recommended dose (RD) of ZD6474 in combination with a fixed standard dose of gemcitabine and capecitabine